- Home
- MAC vs PRCT Comparison
MAC vs PRCT Comparison
Compare MAC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- PRCT
- Stock Information
- Founded
- MAC 1964
- PRCT 2009
- Country
- MAC United States
- PRCT United States
- Employees
- MAC N/A
- PRCT N/A
- Industry
- MAC Real Estate Investment Trusts
- PRCT Medical Specialities
- Sector
- MAC Real Estate
- PRCT Health Care
- Exchange
- MAC Nasdaq
- PRCT Nasdaq
- Market Cap
- MAC 4.4B
- PRCT 5.3B
- IPO Year
- MAC 1994
- PRCT 2021
- Fundamental
- Price
- MAC $19.58
- PRCT $94.45
- Analyst Decision
- MAC Hold
- PRCT Strong Buy
- Analyst Count
- MAC 9
- PRCT 6
- Target Price
- MAC $16.40
- PRCT $89.50
- AVG Volume (30 Days)
- MAC 1.6M
- PRCT 1.2M
- Earning Date
- MAC 11-06-2024
- PRCT 10-28-2024
- Dividend Yield
- MAC 3.45%
- PRCT N/A
- EPS Growth
- MAC N/A
- PRCT N/A
- EPS
- MAC 0.36
- PRCT N/A
- Revenue
- MAC $788,288,000.00
- PRCT $199,843,000.00
- Revenue This Year
- MAC N/A
- PRCT $67.06
- Revenue Next Year
- MAC $3.53
- PRCT $40.59
- P/E Ratio
- MAC $54.93
- PRCT N/A
- Revenue Growth
- MAC N/A
- PRCT 71.71
- 52 Week Low
- MAC $10.75
- PRCT $33.45
- 52 Week High
- MAC $20.40
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- MAC 60.28
- PRCT 58.77
- Support Level
- MAC $18.98
- PRCT $85.75
- Resistance Level
- MAC $19.66
- PRCT $103.81
- Average True Range (ATR)
- MAC 0.68
- PRCT 4.68
- MACD
- MAC -0.02
- PRCT -0.62
- Stochastic Oscillator
- MAC 64.44
- PRCT 48.17
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.